ARS Pharmaceuticals, Inc. - Common Stock SPRY 深 滬
已收盤 09-05 16:00:00 美东时间
10.07
-0.620
-5.80%
華盛通- 最 高10.7284
- 今 開10.70
- 成交量 521.37万股
- 最 低 9.97
- 昨 收 10.69
- 總市值 9.95亿
- 52周最高 18.90
- 市盈率 靜 128.94
- 換手率 0.01%
- 52周最低 9.97
- 委 比 -92.55%
- 總股本 9882.63万
- 歷史最高 63.41
- 量 比 1.13
- 振 幅 7.09%
- 歷史最低 2.55
- 每 手 1
- 風險率 3.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Catalyst Watch: Apple event, Oracle earnings, and Klarna leads an IPO blitz
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Sunday - September...
今天 03:00
美股大行评级 | 潜在涨幅90.8%！Aris Mining获Canaccord Genuity升目标价至17美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Aris Mining"买入"评级，目标价从16.5美元升至17美元；花旗：维持Docusign"买入"评级，目标价从110美元升至115美元
09-05 09:40
Roth Capital Initiates Coverage On ARS Pharmaceuticals with Buy Rating, Announces Price Target of $40
Roth Capital analyst Jason Wittes initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Buy rating and announces Price Target of $40.
09-05 01:46
ARS Pharma drops 9% as Lupin files application for generic neffy
ARS Pharmaceuticals (NASDAQ:SPRY) is down ~9% in Friday trading after disclosing that Indian drugmaker Lupin has filed an ANDA with the U.S. FDA for a generic version of neffy, an epinephrine nasal sp...
08-30 00:04
ARS Pharmaceuticals shares are trading lower following the release of its Q2 financial results.
ARS Pharmaceuticals shares are trading lower following the release of its Q2 fi...
08-13 22:30
ARS Pharmaceuticals Q2 EPS $(0.46), Inline, Sales $15.717M Beat $13.776M Estimate
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. This is a 253.85 percent decrease over losses of $(0.13) per share from the same period last
08-13 19:01
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) will release its quarterly earnings report on...
08-12 23:02
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
ARS Pharmaceuticals, Inc. will host a conference call and webcast on August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its Q2 2025 financial results and business highlights. The event can be registered for and accessed via the company's website. A replay will be available for 30 days. The company focuses on empowering at-risk patients and caregivers with its epinephrine nasal spray, neffy®/EURneffy®.
08-04 12:00
ARS Pharma Says U.K. MHRA Grants Approval For EURneffy For Emergency Treatment Of Allergic Reactions In Adults And Children Who Weigh Greater Than 30 Kg
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactionsALK-Abelló A/S, which owns the rights to market EURneffy
07-18 21:27
